Damoctocog alpha pegol
Damoctocog alfa pegol, nke ana-ere n'okpuru aha Jivi bụ ọgwụ ngwako ọnụ nke eji agwọ hemofilia
Mmetụta ndị ana-ahụkarị na-agụnye isi ọwụwa, ụkwara, agbọ onunu na ahụ ọkụ.
A kwadoro Damoctocog alfa pegol (ihe na-emegide ọbara mgbali elu- recombinant pegylated-aucl) maka iji ọgwụ na United States n'ọnwa Ọgọstụ 2018, na European Union na Nọvemba 2018.[1][2]
Etu esi anụ ọgwụ
[dezie | dezie ebe o si]Na United States, a na-egosi damoctocog alfa pegol maka iji ya mee ihe na ndị okenye na ndị nọ n'afọ iri na ụma (afọ iri na abụọ ma ọ bụ karịa) nwere hemophilia A (nchaghị nke Factor VIII) maka: (1) Ọgwụgwọ na njikwa nke ọbara ọgbụgba; (2) Nchịkwa oge nke ọbara ọwụwa; (3) Mgbochi usoro iji belata ugboro ole ọbara ọgbụrụ.[1]
Na ngalaba irope, ana egosi na ọgwụ damoctocog alfa pegol bu na maka ọgwụgwọ na mgbochi nke ọbara ọgbụgba na ndị a gwọrọ n'oge gara aga na haemophilia A (ihe ọmụmụ nke asatọ).
Edensibia
[dezie | dezie ebe o si]- ↑ 1.0 1.1 Jivi. U.S. Food and Drug Administration (FDA) (29 August 2018). Retrieved on 1 October 2020.
- ↑ (July 2019) "Damoctocog Alfa Pegol: A Review in Haemophilia A". Drugs 79 (10): 1147–1156. DOI:10.1007/s40265-019-01152-7. PMID 31218660.
Njikọ ndị ọzọ
[dezie | dezie ebe o si]- Damoctocog alfa pegol. Drug Information Portal. U.S. National Library of Medicine.
- Clinical trial number NCT01184820 for "Trial to Evaluate the Pharmacokinetics and Safety Profile of BAY94-9027 Following Single and Multiple Dose Administration" at ClinicalTrials.gov
- Clinical trial number NCT01580293 for "A Trial Investigating Safety and Efficacy of Treatment With BAY94-9027 in Severe Hemophilia A (PROTECT-VIII)" at ClinicalTrials.gov
- Clinical trial number NCT01775618 for "Safety and Efficacy of BAY94-9027 in Previously Treated Male Children With Haemophilia A" at ClinicalTrials.gov